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in vitro antibacterial and antifungal properties were tested against some human pathogenic micro-
organisms by employing the disc diffusion technique. A majority of compounds were showing activ-
ity against several of the microorganisms. The relationship between the functional group variation
and the biological activity of the evaluated compounds is discussed. From comparisons of the com-
pounds, 3c was determined to be the most active compound.
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Microbial infections are a growing problem in contemporary
medicine, and the use of antibiotics is common across the9704904902.
C.R. Prakash).
y. Production and hosting by
Saud University.
lsevier
ND license.world. Antimicrobials are among the most commonly pur-
chased drugs worldwide. They are essential treatments espe-
cially in the developing world where infectious diseases are a
common cause of death. In the past 20 years, the incidence
of microbial infection has increased on alarming levels over
the world as a result of antimicrobial resistance. An increasing
number of immuno-compromised patients are a result of HIV
infection, cancer chemotherapy and organ transplantation
which are the major factors contributing to this increase.
The health problem demands to explore and synthesize a novel
class of antimicrobial compounds effective against pathogenic
microorganisms that developed resistance to the antibiotics
used in the current regimen (Yu and Huiyuan, 2002; Koca et
al., 2005).
Isatin (1H-indole-2, 3-dione), an endogenous compound
identiﬁed in many organisms, shows a wide range of biological
338 C.R. Prakash, S. Rajaactivities (Pandeya et al., 2005). The isatin ring is a prominent
structural motif found in several pharmaceutically active com-
pounds. This is mainly due to the easy synthesis and the impor-
tance of pharmacological activity. Therefore, the synthesis and
selective functionalization of isatins have been the focus of ac-
tive research area over the years (Lian-Shun et al., 2011). Isatin
derivatives are reported to show antibacterial (Praveen et al.,
2011) and antifungal (Amalraj et al., 2003) activities.
Fluoroquinolones on the other hand have emerged as one of
the dominant classes of chemotherapeutic drugs for the treat-
ment of various bacterial infections in both community and
hospital settings (Emmerson and Jones, 2003). These antibacte-
rial agents act by inhibiting DNA gyrase (the principal target in
gram-negative bacteria) and topoisomerase IV (the primary
target in gram-positive bacteria) (Charifson et al., 2008). Other
class of antibiotic, such as anthracyclines (Miller and Stoodley,
2011) is used in chemotherapy regimes, and is topoisomerase II
inhibitors by way of drug-DNA intercalation.
Sriram et al. reported Gatiﬂoxacin and Ciproﬂoxacin meth-
ylene isatin derivatives, and a few compounds were more po-
tent than the parent drugs against some of the bacteria
(Sriram et al., 2005, 2006). Recently Lian-Shun (Feng et al.,
2010) reported a series Baloﬂoxacin ethylene isatin derivatives
and 8-OCH3 Ciproﬂoxacin methylene and ethylene isatin
derivatives and showed their in vitro activity against some
mycobacteria (Lian-Shun et al., 2010, 2011). Further, different
5-substituted isatin derivatives were also shown to possess a
wide range of antimicrobial properties (Kandile et al., 2011).
In view of the facts mentioned above and as part of our ini-
tial efforts to discover potentially active new agents, 12 novel
Ciproﬂoxacin methylene isatin derivatives containing different
aromatic aldehydes (3a–3l) were synthesized and evaluated for
their antimicrobial activity.2. Materials and methods
2.1. General
All solvents used were of laboratory grade and were obtained
from SD ﬁne chemicals (Mumbai, India), and Merck (Mum-
bai, India). Ciproﬂoxacin and Ketoconazole are received as
gift samples from Dr. Reddys laboratories, Hyderabad, India.
Melting points were determined in open glass capillary tubes
and are uncorrected. Compounds were routinely checked for
their purity on Silica gel G (Merck) Thin layer chromatogra-
phy (TLC) plates. Iodine chamber and UV lamp were used
for visualization of TLC spots. The IR spectra were recorded
in KBr pellets on (BIO-RAD FTS) FT-IR spectrophotometer.
1H NMR spectra were recorded on Bruker DPX-300 NMR
spectrometer in DMSO-d6 using tetramethylsilane (TMS) as
an internal standard. The chemical shifts are reported in
ppm scale. Elemental data for C, H, and N were within
±0.4% of the theoretical values.
2.2. Test microorganisms and medium
All the microorganisms used in this study were purchased from
CL laboratories, Chennai, India. All the synthesized com-
pounds were screened for antimicrobial activity by paper disc
diffusion technique. The antibacterial activity of the com-
pounds was evaluated against four Gram-positive bacteriaStaphylococcus aureus ATCC 9144, Staphylococcus epidermidis
ATCC 155,Micrococcus luteus ATCC 4698 and Bacillus cereus
ATCC 11778 and three Gram-negative bacteria Escherichia
coli ATCC 25922, Pseudomonas aeruginosa ATCC 2853, and
Klebsiella pneumoniae ATCC 11298. The antifungal activities
of the synthesized compounds were evaluated against two fun-
gi Aspergillus niger ATCC 9029 and Aspergillus fumigatus
ATCC 46645. Bacterial strains were cultured over night at
37 C in Mueller–Hinton broth and the yeast was cultured
overnight at 30 C in YEPDE agar for antibacterial and anti-
fungal activity tests. Test strains were suspended in nutrient
agar to give a ﬁnal density of 5 · 105 cfu/ml.
2.3. Chemistry
2.3.1. Synthesis of 3-(4-aminophenylimino)-5-ﬂuoroindolin
-2-one (1)
The equimolar quantity of 5-ﬂuoro isatin (0.01 mol) and 4-ami-
no aniline (p-phenylene diamine) (0.01 mol) was dissolved in
50 ml of warm ethanol. To this, a few drops of glacial acetic acid
were added. Then the mixture was heated to reﬂux for 1 h. After
standing for approximately 24 h at room temperature, the prod-
ucts were separated by ﬁltration, vacuum dried and recrystal-
lized from ethanol. The compound 1 thus obtained was used
in the next step without further puriﬁcation. Dark brown pow-
der, yield: 75%m.p. 242 C. IR: (KBr, cm1) 3516 (NH2), 1625
(C‚N), 1682 (C‚O). 1HNMR (300 MHz, DMSO-d6, ppm, d):
8.0 (1H, NH), 6.50–7.76 (7H, ArACH), 4.12 (2H, NH2), ESI-
MS: MS: m/z 255 (M+). Anal. Cald for C14H10FN3O: C,
65.88; H, 3.95; N, 16.46. Found: C, 65.90; H, 4.15; N, 16.66.
2.3.2. Synthesis of 7-(4-((3-(4-aminophenylimino)-5-ﬂuoro
-2-oxoindolin-1-yl)methyl)piperazin-1-yl)-1-cyclopropyl
-6-ﬂuoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (2)
To a solution of 1-cyclopropyl-6-ﬂuoro-1,4-dihydro-7-pipera-
zin-1-yl-4-oxo quinoline-3-carboxylic acid (Ciproﬂoxacin,
0.002 mol) in ethanol (50 ml), 3-(4-aminophenylimino)-5-ﬂuor-
oindolin-2-one (1) (0.002 mol) and 37% formalin (1 ml) were
added. The reaction mixture was heated under reﬂux for
24 h. On cooling, the precipitate was collected, washed with
cold ethanol, and recrystallized from a mixture of DMF and
water, to give the compound 2. Dark brown powder, yield:
68% m.p. 296 C. IR: (KBr, cm1) 3516 (NH2), 2784 (COOH),
1625 (C‚N), 1725 (C‚O). 1H NMR (DMSO-d6, 300 MHz) d
ppm: 7.12–8.12 (10H, ArACH), 4.46 (2H, s, NACH2AN of
linker), 3.90 (2H, s, NH2), 2.90 (4H, s, piperazine-4H), 3.32
(4H, s, piperazine-4H), 0.96 (2H, m, cyclopropyl-H), 1.02–
1.10 (2H, m, cyclopropyl-H), 4.02 (1H, m, cyclopropyl-H),
11.52 (1H, COOH). ESI-MS: MS: m/z 598 (M+). Anal. Cald
for C32H28F2N6O4: C, 64.21; H, 4.71; N, 14.04. Found: C,
64.45; H, 4.28; N, 14.41.
2.3.3. General procedure for the synthesis of (3a–3l)
Title compounds (3a–3l)were synthesized by adding 7-(4-((3-(4-
aminophenylimino)-5-ﬂuoro-2-oxoindolin-1-yl)methyl)pipe
razin-1-yl)-1-cyclopropyl-6-ﬂuoro-4-oxo-1,4-dihydroquinoline
-3-carboxylic acid (2) (0.01 mol) as fraction portions with the
well stirred mixture of different aromatic aldehydes (0.01 mol)
in ethanol (50 ml) and few ml of glacial acetic acid. Then this
mixture is reﬂuxed for 8 h and kept aside. The product that sep-
arated out was ﬁltered, dried and recrystallized from ethanol.
The method used for the preparation and isolation of the
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spectral analyses and by thin layer chromatography. The title
compounds are found to be soluble in chloroform, dimethyl
sulfoxide, and dimethylformamide. The physicochemical prop-
erties of the synthesized compounds are given in Table 1.
2.3.4. Spectral data of synthesized compounds (3a–3l)
2.3.4.1. 7-(4-((3-(4-(Benzylideneamino)phenylimino)-5-ﬂuoro-
2-oxindolin-1-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-ﬂuoro-
4-oxo-1,4-dihydroquinoline-3-carboxylic acid (3a). IR (KBr,
cm1) 2699 (COOH), 1624 (C‚N), 1710 (C‚O). 1H NMR
(DMSO-d6, 300 MHz) d ppm: 8.7 (1H, s, N‚CH), 6.6–8.2
(15H, m, ArACH), 4.5 (2H, s, NACH2AN of linker), 2.8
(4H, s, piperazine-4H), 3.5 (4H, s, piperazine-4H), 1.0–1.1
(2H, m, cyclopropyl-H), 1.3–1.5 (2H, m, cyclopropyl-H), 4.1
(1H, m, cyclopropyl-H), 11.5 (1H, COOH). ESI-MS: MS: m/
z 687 (M+).2.3.4.2. 7-(4-((3-(4-(4-Chlorobenzylideneamino)phenylimino)-
5-ﬂuoro-2-oxindolin-1-yl)methyl) piperazin-1-yl)-1-cyclopro-
pyl-6-ﬂuoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (3b).
IR (KBr, cm1) 2716 (COOH), 1625 (C‚N), 1729 (C‚O).
1H NMR (DMSO-d6, 300 MHz) d ppm: 8.8 (1H, s, N‚CH),
6.6–7.7 (14H, m, ArACH), 4.6 (2H, s, NACH2AN of linker),
2.9 (4H, s, piperazine-4H), 3.6 (4H, s, piperazine-4H), 0.9 (2H,
m, cyclopropyl-H), 1.3–1.5 (2H, m, cyclopropyl-H), 3.9 (1H,
m, cyclopropyl-H), 11.5 (1H, COOH). ESI-MS: MS: m/z 721
(M+).
2.3.4.3. 7-(4-((3-(4-(4-Hydroxybenzylideneamino)phenylimi-
no)-5-ﬂuoro-2-oxindolin-1-yl)methyl) piperazin-1-yl)-1-cyclopr
opyl-6-ﬂuoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
(3c). IR (KBr, cm1) 2759 (COOH), 1625 (C‚N), 1729
(C‚O). 1H NMR (DMSO-d6, 300 MHz) d ppm: 8.6 (1H, s,
N‚CH), 7.0–7.9 (14H, m, ArACH), 5.2 (1H, ArAOH), 4.6
(2H, s, NACH2AN of linker), 2.7 (4H, s, piperazine-4H), 3.7
(4H, s, piperazine-4H), 0.8–1.0 (2H, m, cyclopropyl-H), 1.2–
1.4 (2H, m, cyclopropyl-H), 4.1 (1H, m, cyclopropyl-H), 11.8
(1H, COOH). ESI-MS: MS: m/z 703 (M+).
2.3.4.4. 7-(4-((3-(4-(4-Methoxybenzylideneamino)phenylimi-
no)-5-ﬂuoro-2-oxindolin-1-yl) methyl) piperazin-1-yl)-1-cyclo-
propyl-6-ﬂuoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
(3d). IR (KBr, cm1) 2714 (COOH), 1622 (C‚N), 1726
(C‚O). 1H NMR (DMSO-d6, 300 MHz) d ppm: 8.7 (1H, s,
N‚CH), 6.9–7.7 (14H, m, ArACH), 4.5 (2H, s, NACH2AN
of linker), 2.7 (4H, s, piperazine-4H), 3.8 (3H, ArAOCH3),
3.4 (4H, s, piperazine-4H), 0.7–0.9 (2H, m, cyclopropyl-H),
1.0–1.2 (2H, m, cyclopropyl-H), 4.1 (1H, m, cyclopropyl-H),
11.9 (1H, COOH). ESI-MS: MS: m/z 717 (M+).
2.3.4.5. 7-(4-((3-(4-(4-Nitrobenzylideneamino)phenylimino)-
5-ﬂuoro-2-oxindolin-1-yl)methyl) piperazin-1-yl)-1-cyclopro-
pyl-6-ﬂuoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (3e).
IR (KBr, cm1) 2717 (COOH), 1626 (C‚N), 1728 (C‚O).
1H NMR (DMSO-d6, 300 MHz) d ppm: 8.5 (1H, s, N‚CH),
6.6–7.5 (14H, m, ArACH), 4.6 (2H, s, NACH2AN of linker),
2.8 (4H, s, piperazine-4H), 3.6 (4H, s, piperazine-4H), 0.7–0.9
(2H, m, cyclopropyl-H), 1.1–1.2 (2H, m, cyclopropyl-H), 4.1
(1H, m, cyclopropyl-H), 11.5 (1H, COOH). ESI-MS: MS: m/
z 732 (M+).2.3.4.6. 7-(4-((3-(4-(2-Hydroxybenzylideneamino)phenylimi-
no)-5-ﬂuoro-2-oxindolin-1-yl)methyl) piperazin-1-yl)-1-cyclo-
propyl-6-ﬂuoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
(3f). IR (KBr, cm1) 2714 (COOH), 1624 (C‚N), 1727
(C‚O). 1H NMR (DMSO-d6, 300 MHz) d ppm: 8.7 (1H, s,
N‚CH), 7.1–8.1 (14H, m, ArACH), 5.0 (1H, ArAOH), 4.3
(2H, s, NACH2AN of linker), 2.7 (4H, s, piperazine-4H), 3.4
(4H, s, piperazine-4H), 0.8–0.9 (2H, m, cyclopropyl-H), 1.3–
1.4 (2H, m, cyclopropyl-H), 3.9 (1H, m, cyclopropyl-H), 11.7
(1H, COOH). ESI-MS: MS: m/z 703 (M+).
2.3.4.7. 7-(4-((3-(4-(4-Methylbenzylideneamino) phenylimi-
no)-5-ﬂuoro-2-oxindolin-1-yl)methyl) piperazin-1-yl)-1-cyclo-
propyl-6-ﬂuoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
(3g). IR (KBr, cm1) 2713 (COOH), 1624 (C‚N), 1711
(C‚O). 1H NMR (DMSO-d6, 300 MHz) d ppm: 8.7 (1H, s,
N‚CH), 6.6–8.3 (14H, m, ArACH), 4.3 (2H, s, NACH2AN
of linker), 2.8 (4H, s, piperazine-4H), 3.2 (4H, s, piperazine-
4H), 0.9–1.0 (2H, m, cyclopropyl-H), 1.2–1.4 (2H, m, cyclo-
propyl-H), 3.9 (1H, m, cyclopropyl-H), 2.2 (3H, ArACH3),
11.9 (1H, COOH). ESI-MS: MS: m/z 700 (M+).
2.3.4.8. 7-(4-((3-(4-(3,4,5-Trimethoxybenzylideneamino)phe-
nylimino)-5-ﬂuoro-2-oxindolin-1-yl) methyl)piperazin-1-yl)-1-
cyclopropyl-6-ﬂuoro-4-oxo-1,4-dihydroquinoline-3-carboxylic-
acid (3h). IR (KBr, cm1) 2696 (COOH), 1624 (C‚N), 1708
(C‚O). 1H NMR (DMSO-d6, 300 MHz) d ppm: 8.7 (1H, s,
N‚CH), 7.1–8.0 (12H, m, ArACH), 4.6 (2H, s, NACH2AN
of linker), 3.6 (9H, ArAOCH3), 2.7 (4H, s, piperazine-4H),
3.3 (4H, s, piperazine-4H), 0.9 (2H, m, cyclopropyl-H), 1.2–
1.4 (2H, m, cyclopropyl-H), 3.8 (1H, m, cyclopropyl-H), 11.6
(1H, COOH). ESI-MS: MS: m/z 777 (M+).
2.3.4.9. 7-(4-((3-(4-(4-Hydroxy,3-methoxybenzylideneami-
no)phenylimino)-5-ﬂuoro-2-oxindolin-1-yl) methyl)piperazin-
1-yl)-1-cyclopropyl-6-ﬂuoro-4-oxo-1,4-dihydroquinoline-3-carb-
oxylicacid (3i). IR (KBr, cm1) 2702 (COOH), 1625 (C‚N),
1707 (C‚O). 1H NMR (DMSO-d6, 300 MHz) d ppm: 8.5
(1H, s, N‚CH), 6.8–7.7 (13H, m, ArACH), 5.1 (1H,
ArAOH), 4.6 (2H, s, NACH2AN of linker), 3.6 (3H,
ArAOCH3), 2.7 (4H, s, piperazine-4H), 3.2 (4H, s, pipera-
zine-4H), 0.8–0.9 (2H, m, cyclopropyl-H), 1.1–1.3 (2H, m,
cyclopropyl-H), 4.1 (1H, m, cyclopropyl-H), 11.6 (1H,
COOH). ESI-MS: MS: m/z 733 (M+).
2.3.4.10. 7-(4-((3-(4-(3-Nitrobenzylideneamino) phenylimino)-
5-ﬂuoro-2-oxindolin-1-yl)methyl) piperazin-1-yl)-1-cyclopro-
pyl-6-ﬂuoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (3j).
IR (KBr, cm1) 2722 (COOH), 1629 (C‚N), 1710 (C‚O).
1H NMR (DMSO-d6, 300 MHz) d ppm: 8.8 (1H, s, N‚CH),
6.7–7.9 (14H, m, ArACH), 4.4 (2H, s, NACH2AN of linker),
2.8 (4H, s, piperazine-4H), 3.4 (4H, s, piperazine-4H), 0.7–0.9
(2H, m, cyclopropyl-H), 1.1–1.4 (2H, m, cyclopropyl-H), 3.8
(1H, m, cyclopropyl-H), 11.8 (1H, COOH). ESI-MS: MS: m/
z 732 (M+).
2.3.4.11. 7-(4-((3-(4-(4-(N,N-dimethylamino)benzylideneami-
no)phenylimino)-5-ﬂuoro-2-oxindolin-1-yl) methyl)piperazin-1-
yl)-1-cyclopropyl-6-ﬂuoro-4-oxo-1,4-dihydroquinoline-3-carbox
ylic acid (3k). IR (KBr, cm1) 2752 (COOH), 1632 (C‚N),
1720 (C‚O). 1H NMR (DMSO-d6, 300 MHz) d ppm: 8.6
(1H, s, N‚CH), 7.2–8.1 (14H, m, ArACH), 4.4 (2H, s,
Table 1 Physicochemical data of all synthesized test compounds (3a–3l).
Compound Ar m.p. (C) Yield (%) Molecular formula Analysis (%), found (calc.): C; H; N
3a 204–208 48 C39H32F2N6O4 68.02 (68.21); 4.45 (4.70); 12.44 (12.24)
3b
Cl
211–216 46 C39H31ClF2N6O4 64.82 (64.95); 4.21 (4.33); 11.68 (11.65)
3c
OH
192–196 71 C39H32F2N6O5 66.84 (66.66); 4.72 (4.59); 11.99 (11.96)
3d
OCH3
162–164 66 C40H34F2N6O5 67.27 (67.03); 4.74 (4.78); 11.81 (11.73)
3e
NO2
190–192 40 C39H31F2N7O6 63.90 (64.02); 4.20 (4.27); 13.49 (13.40)
3f
HO
216–218 52 C39H32F2N6O5 66.86 (66.66); 4.70 (4.59); 11.84 (11.96)
3g
CH3
238–240 54 C40H34F2N6O4 68.12 (68.56); 4.60 (4.89); 12.30 (11.99)
3h
OCH3
OCH3
OCH3
222–224 72 C42H38F2N6O7 65.30 (64.94); 4.72 (4.93); 11.02 (10.84)
3i
OH
OCH3
182–184 50 C40H34F2N6O6 65.77 (65.57); 4.82 (4.68); 11.67 (11.47)
3j
NO2
178–180 47 C39H31F2N7O6 63.82 (64.02); 4.38 (4.27); 13.12 (13.40)
3k
N
CH3
CH3
152–154 62 C41H37F2N7O4 67.22 (67.48); 5.32 (5.11); 13.21 (13.44)
3l
HC=HC
242–244 52 C41H34F2N6O4 69.42 (69.09); 4.62 (4.81); 11.98 (11.79)
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piperazine-4H), 0.8 (2H, m, cyclopropyl-H), 1.1–1.2 (2H, m,
cyclopropyl-H), 4.0 (1H, m, cyclopropyl-H), 2.4 (6H, N-
(CH3)2), 11.7 (1H, COOH). ESI-MS: MS: m/z 730 (M
+).
2.3.4.12. 1-Cyclopropyl-6-ﬂuoro-7-(4-((-5-ﬂuoro-2-oxo-3-(4-
(3-phenylallylideneamino) phenylimino) indolin-1-yl)methyl)
piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
(3l). IR (KBr, cm1) 2715 (COOH), 1618 (C‚N), 1716
(C‚O). 1H NMR (DMSO-d6, 300 MHz) d ppm: 8.7 (1H, s,
N‚CH), 7.1–8.1 (15H, m, ArACH), 6.4 (1H, CH‚CH), 5.3
(1H, CH‚CH), 4.6 (2H, s, NACH2AN of linker), 2.9 (4H,
s, piperazine-4H), 3.6 (4H, s, piperazine-4H), 0.7–0.9 (2H, m,
cyclopropyl-H), 1.1–1.3 (2H, m, cyclopropyl-H), 4.0 (1H, m,
cyclopropyl-H), 11.7 (1H, COOH). ESI-MS: MS: m/z 713
(M+).
3. Biological activities
3.1. Paper disc diffusion technique
The sterilized (Gillespie, 1994) (autoclaved at 120 C for
30 min) medium (40–50 C) was inoculated (1 ml/100 ml of
medium) with the suspension (5 · 105 cfu/ml) of the microor-
ganism (matched to McFarland barium sulphate standard)
and poured into a petridish to give a depth of 3–4 mm. The pa-
per impregnated with the test compounds (50, 100 and 150 lg/
ml in dimethyl formamide) was placed on the solidiﬁed med-
ium. The plates were pre-incubated for 1 h at room tempera-
ture and incubated at 37 C for 24 and 48 h for antibacterial
and antifungal activities, respectively. Ciproﬂoxacin (100 lg/
ml/disc) and Ketoconazole (100 lg/ml/disc) were used as stan-
dard for anti-bacterial and anti-fungal activities, respectively.
All the observed zones of inhibition results are shown in Table
2.
3.2. Minimum inhibitory concentration (MIC)
MIC of the compound was determined by agar streak dilution
method (Hawkey and Lewis, 1994). A stock solution of the syn-
thesized compound (100 lg/ml) in dimethyl formamide was pre-
pared and graded quantities of the test compounds were
incorporated in a speciﬁed quantity ofmolten sterile agar (nutri-
ent agar for anti-bacterial activity and Sabouraud’s dextrose
agar medium for anti-fungal activity). A speciﬁed quantity of
the medium (40–50 C) containing the compound was poured
into a petridish to give a depth of 3–4 mm and allowed to solid-
ify. Suspension of the micro-organism was prepared to contain
approximately 5 · 105 cfu/ml and applied to plates with seri-
ally diluted compounds in dimethyl formamide to be tested
and incubated at 37 C for 24 h and 48 h for bacteria and fungi,
respectively. The MIC was considered to be the lowest concen-
tration of the test substance exhibiting no visible growth of bac-
teria or fungi on the plate. The observed MIC is presented in
Table 3.
4. Results and discussion
4.1. Chemistry
In this study, we synthesized a series of novel Schiff and man-
nich bases of isatin derivative by substituting different
Table 3 MIC (minimum inhibitory concentration in lg/ml) of synthesized compounds (3a–3l).
Compounds S. aureus S. epidermidis M. luteus E. coli P. aeruginosa K. pneumoniae A. niger A. fumigatus
3a 62.5 31.25 – 62.5 61.25 – 62.5 62.5
3b 31.25 62.5 31.25 31.25 62.5 31.25 31.25 62.5
3c 7.81 15.62 15.62 15.62 7.81 15.62 15.62 7.81
3d 15.62 31.25 31.25 15.62 31.25 31.25 15.62 31.25
3e 62.5 – 125 – 62.5 62.5 62.5 62.5
3f 62.5 31.25 31.25 31.25 62.5 31.25 31.25 31.25
3g 31.25 15.62 – 31.25 31.25 62.5 31.25 31.25
3h 15.62 7.81 7.81 31.25 15.62 15.62 31.25 15.62
3i 31.25 15.62 15.62 31.25 – 3.9 15.62 31.25
3j – 125 62.5 – – 62.5 62.5 62.5
3k 15.62 15.62 7.81 31.25 7.81 15.62 7.81 15.62
3l 62.5 31.25 – – 62.5 125 62.5 62.5
Ciproﬂoxacin 15.62 7.81 7.81 15.62 7.81 3.9 – –
Ketoconazole – – – – – – 15.62 7.81
342 C.R. Prakash, S. Rajaaromatic aldehydes at the 3rd position and linking Ciproﬂox-
acin at the N1 position with formalin. Initially, 5-ﬂuoro isatin
and 4-amino aniline were used as starting materials to produce
3-(4-aminophenylimino)-5-ﬂuoroindolin-2-one by a condensa-
tion reaction, which proceeds selectively on the carbonyl group
in position 3 of the isatin ring. Furthermore, this compound
was treated with Ciproﬂoxacin and formalin gave 7-(4-((3-(4-
aminophenylimino)-5-ﬂuoro-2-oxoindolin-1-yl)methyl)pipera-
zin-1-yl)-1-cyclopropyl-6-ﬂuoro-4-oxo-1,4-dihydroquinoline-
3-carboxylic acid. Finally this mannich base was treated with
different aromatic aldehydes in the presence of glacial acetic
acid, and a variety of Schiff base derivatives have been isolated
according to the synthetic Scheme 1.
IR, 1H NMR, mass spectra, and elemental analyses of the
synthesized compounds are in accordance with the assigned
structures. The IR spectra of all synthesized compounds
showed some characteristic peaks indicating the presence of
particular groups. The absorption bands at 2696–2759 cm1,
1707–1729 cm1, and weak band at 1618–1632 cm1, which
can be assignable to COOH, C‚O, and C‚N (azomethine
linkage) vibrations respectively. IR spectrum of 7-(4-((3-(4-
(4-hydroxybenzylideneamino)phenylimino)-5-ﬂuoro-2-oxindo-
lin-1-yl)methyl) piperazin-1-yl)-1-cyclopropyl-6-ﬂuoro-4-oxo-
1,4-dihydroquinoline-3-carboxylic acid (3c) was shown in the
absorption band in the region of 3345–3420 cm1 which may
be assigned to OAH stretching.
The proton magnetic resonance spectrums of synthesized
compounds were recorded in DMSO-d6. The following conclu-
sions can be derived by comparing the spectra of synthesized
compounds:
 Two sets of singlet at 2.7–3.6 ppm for piperazine-4H.
 Two sets of multiplet at 0.7–1.4 and 3.8–4.2 ppm for cyclo-
propyl-5H.
 A singlet at 8.4–8.8 for N‚CH group.
 A singlet at 4.4–4.8 ppm corresponding to ANCH2NA
group for methylene derivatives.
4.2. Antimicrobial activity
In this study, all the synthesized compounds were evaluated
for their in vitro antibacterial and antifungal activity. A com-
parison of antimicrobial activity of the synthesized compounds
with that of standard drugs was effectively presented in Table2. Compounds 3c, 3k, 3h and 3i showed excellent antimicrobial
properties towards all the microorganisms except B. cereus
ATCC 11778. Compound 3c showed remarkable activity com-
pared to Ciproﬂoxacin against S. aureus ATCC 9144 and P.
aeruginosa ATCC 2853. Further, compound 3k showed more
activity against K. pneumoniae ATCC 11298 when compared
with the reference drug Ciproﬂoxacin.
Compounds 3d, 3f, 3g and 3b showed moderate to average
antibacterial and antifungal activity. The compound 3d
possesses the same activity againstM. luteus ATCC 4698 com-
pared with standard than the other compounds. Unfortu-
nately, none of the synthesized derivatives in this series
showed any activity against B. cereus ATCC 11778. All com-
pounds except 3e were found to display signiﬁcant activity
against S. epidermidis ATCC 155. The compounds other than
3l, 3a, 3j and 3e demonstrated signiﬁcant levels of activity
against fungus strain A. niger ATCC 9029. All the compounds
showed moderate to signiﬁcant activity against A. fumigatus
ATCC 46645. Among the compounds synthesized it was noted
that 3h was more potent against A. fumigatus ATCC 46645
than the reference compound Ketoconazole.
All the synthesized compounds were subjected to MIC
(minimum inhibitory concentration) studies against all the
microorganisms except B. cereus ATCC 11778. The MICs of
Ciproﬂoxacin and Ketoconazole were determined in parallel
experiments in order to control the sensitivity of the test organ-
isms. MIC values of the compounds and the standards are pre-
sented in Table 3. As seen in Table 3 While all compounds
showed lower activities than standard against S. aureus, 3d,
3h and 3k showed the same activity (MIC: 15.62 lg/ml). More-
over 3c demonstrated better activity (MIC: 7.81 lg/ml) than
Ciproﬂoxacin. Compound 3h showed the same activity
(MIC: 7.81 lg/ml) against S. epidermidis, while other com-
pounds exhibited lower activity (MIC: 15.62–125 lg/ml).
Compound 3e showed very least activity (MIC: >125 lg/ml)
than standard. Compounds 3h and 3k showed the same activ-
ity (MIC: 7.81 lg/ml) as Ciproﬂoxacin againstM. luteus, while
others demonstrated lower activity than standard. All the com-
pounds showed lower activity except 3c and 3d (showed the
same activity with MIC: 15.62 lg/ml) against E. coli. Com-
pounds 3c and 3k showed the same activity (MIC: 7.81 lg/
ml) as Ciproﬂoxacin against P. aeruginosa. Only compound
3i showed the same activity (MIC: 3.9 lg/ml) as standard
against K. pneumoniae, while others showed the lower activity.
Compound 3k demonstrated better activity (MIC: 7.81 lg/ml)
Scheme 1 Schematic representation of the synthesized compounds.
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activity (MIC: 15.62 lg/ml) as standard remaining compounds
showed lower activity against A. niger. Compounds 3c showed
equal activity (MIC: 7.81 lg/ml) against A. fumigatus while the
others have lower activity (MIC: 15.62–62.5 lg/ml) than stan-
dard (MIC: 7.81 lg/ml).4.3. Structure Activity Relationships (SAR)
The current results revealed that most of the synthesized deriv-
atives exhibited signiﬁcant antimicrobial activity. The most
potent antibacterial and antifungal activity exhibited by com-
pound 3c, 3k, 3h and 3i might be due to the presence of
344 C.R. Prakash, S. Rajaelectron donating substituent like hydroxy, N-dimethyl amino,
3,4,5-trimethoxy and 4-hydroxy-3-methoxy group respectively
on phenyl ring of the 5-ﬂuoro isatin. Similarly compound 3d,
3f and 3g also exhibited signiﬁcant antimicrobial activity due
to the above said reason. While other compounds (although
they contain electron withdrawing substituents such as nitro
and chloro groups (3j and 3b)) do not exhibit signiﬁcant
in vitro antimicrobial activity. The MIC values were deter-
mined as the lowest concentration that totally inhibited visible
growth of the microorganisms. The chemical structure and
antimicrobial activity relationship of the synthesized com-
pounds revealed that the compounds having electron with-
drawing moiety exhibited least activity when compared with
compounds having electron releasing moieties.5. Conclusions
In summary, a series of novel Ciproﬂoxacin methylene isatin
derivatives incorporating different aromatic aldehydes were
synthesized and characterized by FT-IR, 1H NMR, mass
spectroscopy and elemental analysis. These derivatives were
evaluated for their in vitro antimicrobial activity against seven
bacteria (including four gram positive and three gram nega-
tive) and two fungi strains. In general, electron donating
group substituted derivatives showed more remarkable anti-
microbial properties than electron withdrawing compounds.
Ciproﬂoxacin methylene isatin derivatives incorporated with
p-hydroxy group 3c show better activity than Ciproﬂoxacin
and Ketoconazole. However, the electron withdrawing
groups like nitro and chloro substituted derivatives showed
least activity towards tested microorganisms. These results
indicate that electron donating group substituted derivatives
may be useful leads for antimicrobial drug development in
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